ANIP vs RNAC
ANIP: A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions. RNAC: Cartesian Therapeutics is pioneering mRNA-engineered cell therapies designed to provide a precision immune reset for patients with autoimmune diseases, administered in an outpatient setting without the need for lymphodepleting chemotherapy.
Side-by-side fundamentals
| Metric | ANIP | RNAC | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $78.37 | $7.79 | |
| Market cap as of 2026-07-31 | $1.9B | $229M | |
| P/E as of 2026-07-31 | 19.99 | n/a | |
| PEG as of 2026-07-31 | 1.17 | n/a | |
| Net margin as of 2026-07-31 | +10.0% | -8550.6% | ANIP higher |
| Gross margin as of 2026-07-31 | +60.8% | n/a | |
| Operating margin as of 2026-07-31 | +13.4% | -8338.9% | ANIP higher |
| ROE as of 2026-07-31 | +17.8% | -3215.8% | ANIP higher |
| ROA as of 2026-07-31 | +6.6% | -45.1% | ANIP higher |
| Debt / equity as of 2026-07-31 | 1.09 | 0.00 | RNAC lower |
| Revenue growth (YoY) as of 2026-07-31 | +37.0% | -94.9% | ANIP higher |
| Revenue CAGR (3y) SEC XBRL | +40.8% | -84.7% | ANIP higher |
| Dividend yield as of 2026-07-31 | +0.0% | n/a | |
| Beta as of 2026-07-31 | 0.48 | 0.66 | |
| 1-year return as of 2026-07-27 close | +16.1% | -41.6% | ANIP higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.